Hengrui Pharma and U.S.-based Kailera Therapeutics announced on July 15, 2025, that their dual GLP-1/GIP receptor agonist HRS9531 injection achieved positive topline outcomes in a Phase III clinical trial (HRS9531-301) for Chinese subjects with obesity or overweight.
In the 48-week study involving 567 participants averaging 93 kg baseline weight, all HRS9531 dose groups (2mg, 4mg, 6mg) demonstrated superiority over placebo across co-primary and key secondary endpoints. Primary analysis revealed the 6mg cohort achieved 17.7% mean weight reduction (placebo-adjusted: 16.3%), with 88.0% of subjects losing ≥5% body weight and 44.4% achieving ≥20% weight loss. Supplementary analysis showed up to 19.2% mean weight reduction (placebo-adjusted: 17.7%).
The candidate exhibited favorable safety and tolerability, with predominantly mild-to-moderate gastrointestinal treatment-emergent adverse events consistent with established GLP-1 therapies. These findings align with prior Phase II data where an 8mg dose yielded 22.8% weight reduction after 36 weeks without plateauing.
Hengrui Pharma intends to submit a New Drug Application for long-term weight management in China imminently, while Kailera advances global development of the asset (designated KAI-9531) outside Greater China.
The multicenter, randomized, double-blind trial (NCT06396429) evaluated adults with obesity (BMI≥28kg/m²) or overweight (BMI≥24kg/m²) plus weight-related comorbidities. Among 531 completers, all active arms met superiority endpoints with safety profiles matching earlier observations.
Developed internally by Hengrui, HRS9531 represents a dual-receptor agonist targeting obesity and type 2 diabetes. Over 2,000 Chinese subjects have received the therapy across trials. The 2024 licensing agreement grants Kailera ex-China rights for up to $6 billion in milestones plus 19.9% equity.
Hengrui's metabolic portfolio includes four approved products and multiple clinical-stage assets: oral GLP-1 agonist HRS-7535, triple agonist HRS-4729, weekly insulin SHR-3167, and insulin/GLP-1R combo HR17031. Two candidates—long-acting insulin INS068 and SGLT2i/DPP4i/metformin combo HR20031—await regulatory review.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.